Aimmune Therapeutics Inc. (AIMT)

20.64
0.02 0.10
NASDAQ : Health Technology
Prev Close 20.66
Open 20.73
Day Low/High 20.45 / 21.00
52 Wk Low/High 16.95 / 36.12
Volume 587.05K
Avg Volume 521.90K
Exchange NASDAQ
Shares Outstanding 62.67M
Market Cap 1.41B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Aimmune Therapeutics Presents Results From The Positive, Pivotal Phase 3 PALISADE Trial Of AR101 For Peanut Allergy At AAAAI-WAO

Aimmune Therapeutics Presents Results From The Positive, Pivotal Phase 3 PALISADE Trial Of AR101 For Peanut Allergy At AAAAI-WAO

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced that the results of its pivotal Phase 3 PALISADE trial of AR101 for the...

Aimmune Therapeutics Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Aimmune Therapeutics Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the underwriters of its previously announced underwritten...

Aimmune Therapeutics To Host Analyst And Investor Event Following Oral Late-Breaking Presentation Of Phase 3 PALISADE Results On Sunday, March 4, At The AAAAI-WAO Joint Congress In Orlando

Aimmune Therapeutics To Host Analyst And Investor Event Following Oral Late-Breaking Presentation Of Phase 3 PALISADE Results On Sunday, March 4, At The AAAAI-WAO Joint Congress In Orlando

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Analyst and Investor Event on the evening of March 4,...

Aimmune Therapeutics Announces Closing Of Public Offering Of Common Stock

Aimmune Therapeutics Announces Closing Of Public Offering Of Common Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the completion of its previously announced underwritten public...

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

Aimmune Therapeutics Announces Pricing Of Public Offering Of Common Stock

Aimmune Therapeutics Announces Pricing Of Public Offering Of Common Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering of 5,500,000 shares...

Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock

Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has commenced an underwritten public offering of up to...

Noteworthy Tuesday Option Activity: AIMT, W, MCRI

Noteworthy Tuesday Option Activity: AIMT, W, MCRI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Aimmune Therapeutics Inc , where a total volume of 5,297 contracts has been traded thus far today, a contract volume which is representative of approximately 529,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 121.7% of AIMT's average daily trading volume over the past month, of 435,400 shares.

Aimmune Therapeutics' Pivotal Phase 3 PALISADE Trial Of AR101 Meets Primary Endpoint In Patients With Peanut Allergy

Aimmune Therapeutics' Pivotal Phase 3 PALISADE Trial Of AR101 Meets Primary Endpoint In Patients With Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its pivotal Phase 3 PALISADE efficacy trial of AR101 met the...

Aimmune Therapeutics Expands Scientific Advisory Board With Appointments Of George Du Toit, M.B., B.Ch., And Wayne Shreffler, M.D., Ph.D.

Aimmune Therapeutics Expands Scientific Advisory Board With Appointments Of George Du Toit, M.B., B.Ch., And Wayne Shreffler, M.D., Ph.D.

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the expansion of its Scientific Advisory Board with the...

Aimmune Therapeutics Announces Presentations At 2018 AAAAI-WAO Joint Congress

Aimmune Therapeutics Announces Presentations At 2018 AAAAI-WAO Joint Congress

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data during a late-breaking oral abstract...

There Is Still Plenty of Strong, Tradable Action

There Is Still Plenty of Strong, Tradable Action

This market may be extended by just about any measure, but that doesn't mean you should be fighting it.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

You Can't Reason With a Steamroller

You Can't Reason With a Steamroller

The momentum is crushing everything in its way.

Aimmune Therapeutics Broadens And Extends Supply Agreement With Golden Peanut And Tree Nuts For AR101 For Peanut Allergy

Aimmune Therapeutics Broadens And Extends Supply Agreement With Golden Peanut And Tree Nuts For AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced an expansion and extension of its exclusive supply agreement with...

Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 PALISADE Trial Of AR101 For Peanut Allergy

Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 PALISADE Trial Of AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced its outlook for the coming year, including its plans to report...

Aimmune Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Aimmune Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.

Volume Slows Ahead of Christmas Holiday

Volume Slows Ahead of Christmas Holiday

Breadth is slightly negative as markets ease into 3-day weekend.

Blockchain Will Be a Top Investing Theme in 2018

Blockchain Will Be a Top Investing Theme in 2018

The applications for this distributed ledger technology are endless.

Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling

Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling

The republican loss in the Alabama special election for U.S. senate had only a brief imapct on stock futures.

Aimmune Therapeutics To Participate In The BMO Capital Markets 2017 Prescriptions For Success Healthcare Conference On December 14

Aimmune Therapeutics To Participate In The BMO Capital Markets 2017 Prescriptions For Success Healthcare Conference On December 14

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside...

Aimmune Therapeutics To Host Investor Symposium On Peanut Allergy Treatment With Leading Expert Allergists On Friday, December 1

Aimmune Therapeutics To Host Investor Symposium On Peanut Allergy Treatment With Leading Expert Allergists On Friday, December 1

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017.

As Dip Buyers Jump in, Stay Focused on Stock Picking

As Dip Buyers Jump in, Stay Focused on Stock Picking

Small-caps are lagging and breadth is negative, but the computer algorithms are very impressive.

Aimmune Therapeutics Announces Third Quarter 2017 Financial Results And Planned Retirement Of CEO By The End Of 2018

Aimmune Therapeutics Announces Third Quarter 2017 Financial Results And Planned Retirement Of CEO By The End Of 2018

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2017.

Selling Subsides, but Market's Still a Mess

Selling Subsides, but Market's Still a Mess

Facebook, Alibaba sell off on very good reports.

Aimmune Therapeutics To Participate In Four Investor Conferences In November

Aimmune Therapeutics To Participate In Four Investor Conferences In November

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in...

Aimmune Therapeutics Announces Publication In The Journal Of Allergy And Clinical Immunology: In Practice Of Positive AR101 Data From ARC001 Phase 2 Clinical Trial

Aimmune Therapeutics Announces Publication In The Journal Of Allergy And Clinical Immunology: In Practice Of Positive AR101 Data From ARC001 Phase 2 Clinical Trial

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the online publication of positive data from its ARC001 Phase 2...

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.

The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

Here's what you need to know now for Monday, Oct. 23.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.